ArticleChinese medical journal2026
Rhein attenuates severe acute pancreatitis-associated intestinal injury through PPARγ regulating macrophage activation.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute pancreatitis (SAP) often leads to life-threatening multiorgan dysfunction, with intestinal barrier failure being a key driver of systemic inflammation. Although Rhein shows efficacy in SAP, its mechanism for protecting against pancreatitis-associated intestinal injury remains unclear. This study aimed to elucidate the mechanism of Rhein in pancreatitis-associated intestinal injury (PAII), with a focus on intestinal macrophage polarization and peroxisome proliferator-activated receptor γ (PPARγ) signaling.
methodsSAP was induced in male C57BL/6J mice by intraperitoneal injections of cerulein and lipopolysaccharide (LPS). Pancreatic and intestinal histopathology were assessed by hematoxylin and eosin staining using both paraffin and frozen sections. The expression of PPARγ, NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome components, and macrophage polarization markers was examined by real-time quantitative polymerase chain reaction (RT-qPCR), Western blotting, and immunofluorescence. RT-qPCR was also used to quantify the messenger RNA (mRNA) levels of pro-inflammatory cytokines (interleukin [ IL ]- 1β , IL-6 , tumor necrosis factor [ TNF ]- α , mono-cyte chemoattractant protein-1 [ MCP-1 ]) and the anti-inflammatory cytokine IL-10 in colonic tissues. Reactive oxygen species (ROS) levels in colonic tissues were detected by dihydroethidium staining. Serum levels of lipopolysaccharide were measured by enzyme-linked immunosorbent assay (ELISA). For in vitro mechanistic studies, primary bone marrow-derived macrophages isolated from C57BL/6J mice were stimulated with LPS and interferon-γ to induce M1 macrophage polarization, with or without Rhein treatment.
resultsSAP-induced intestinal injury was characterized by downregulated PPARγ, NLRP3 inflammasome hyperactivation, and dominant M1 macrophage polarization. Rhein restored PPARγ, suppressed NLRP3, and reduced secretion of key M1-sustaining cytokines ( IL-6 , IL-1β , and TNF - α ). This attenuated the proinflammatory milieu, indirectly facilitating an M1-to-M2 phenotypic shift. All benefits were abolished by PPARγ antagonism.
conclusionRhein alleviates pancreatitis-associated intestinal injury by activating PPARγ, which suppresses the NLRP3 inflammasome and downstream proinflammatory cytokine cascade, thereby modulating macrophage polarization. The PPARγ-NLRP3 axis is a crucial regulatory pathway and potential therapeutic target in SAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.